The FDA has approved supplemental labeling for Kybella, Allergan Aesthetics' deoxycholic acid injection for submental fullness. The update incorporates new clinical data, though the agency has not disclosed specifics. This is a modest but meaningful win for Allergan in a category where Kybella remains the only FDA-cleared injectable for chin fat reduction.
Kybella's market position has been stable but not explosive. The procedure requires multiple sessions (typically two to four), patient downtime is real (swelling, bruising, potential nerve effects), and the patient pool self-selects for those genuinely bothered by submental fat rather than seeking it as an impulse treatment. The labeling refresh signals Allergan's confidence in durability data and may unlock messaging around longevity or patient selection criteria that practices can use to refine candidacy conversations.